Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 3301 - 3400
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 3301 | 26599204 |
US |
6 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3302 | 26599259 |
US |
27 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3303 | 26599276 |
US |
67 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3304 | 26599279 |
US |
2 | |
Dermatitis atopic, Rash, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 3305 | 26599286 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3306 | 26599287 |
US |
32 | 2 |
Pruritus, Product dose omission in error, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3307 | 26601302 |
US |
23 | 2 |
Pneumonia, Arthralgia, Dermatitis atopic, Headache, Secretion discharge, |
||||
UPADACITINIB, UPADACITINIB, RISANKIZUMAB-RZAA, RISANKIZUMAB-RZAA, |
||||
| 3308 | 26601496 |
US |
42 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3309 | 26601518 |
US |
15 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3310 | 26601541 |
US |
12 | 1 |
Dermatitis atopic, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 3311 | 26601550 |
US |
78 | 1 |
Eczema, Product dose omission issue, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3312 | 26601556 |
US |
64 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3313 | 26601583 |
US |
1 | |
Lung disorder, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3314 | 26601587 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3315 | 26601594 |
US |
2 | |
Dermatitis atopic, Rash pruritic, Skin exfoliation, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 3316 | 26601596 |
US |
63 | 2 |
Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3317 | 26601598 |
US |
70 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 3318 | 26601600 |
US |
2 | 2 |
Nasopharyngitis, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3319 | 26601602 |
US |
6 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3320 | 26601607 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3321 | 26601609 |
US |
2 | |
Pruritus, Dry skin, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3322 | 26601613 |
US |
16 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3323 | 26601615 |
US |
48 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3324 | 26601616 |
US |
57 | 2 |
Dermatitis atopic, Erythema, Pruritus, |
||||
DUPILUMAB, |
||||
| 3325 | 26601617 |
US |
40 | 2 |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 3326 | 26601624 |
US |
18 | 1 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 3327 | 26601631 |
US |
49 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3328 | 26601656 |
US |
18 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3329 | 26601657 |
US |
50 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3330 | 26601661 |
US |
44 | 2 |
Back pain, Fatigue, Nasopharyngitis, Dermatitis atopic, Chronic sinusitis, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 3331 | 26601662 |
US |
45 | 1 |
Dermatitis atopic, Erythema, Pruritus, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 3332 | 26601663 |
US |
78 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3333 | 26601665 |
US |
5 | 1 |
Dermatitis atopic, Pruritus, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3334 | 26601730 |
US |
76 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3335 | 26601796 |
US |
52 | 2 |
Injection site swelling, Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 3336 | 26591248 |
US |
9 | 2 |
Eczema, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3337 | 26591307 |
US |
13 | 2 |
Dermatitis atopic, Pruritus, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3338 | 26591312 |
US |
4 | 1 |
Pain, Dry skin, Skin exfoliation, Sleep disorder, Pruritus, Dermatitis atopic, Ocular hyperaemia, |
||||
DUPILUMAB, |
||||
| 3339 | 26591386 |
US |
57 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3340 | 26591399 |
US |
84 | 1 |
Dermatitis atopic, Pruritus, Dry skin, Skin fissures, Skin exfoliation, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3341 | 26591407 |
US |
1 | |
Dermatitis atopic, Rash, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3342 | 26591409 |
US |
59 | 1 |
Pruritus, Rash erythematous, Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 3343 | 26591411 |
US |
1 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 3344 | 26591469 |
US |
55 | 2 |
Dermatitis atopic, Pruritus, Skin burning sensation, Therapeutic response shortened, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3345 | 26591470 |
US |
47 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 3346 | 26591585 |
US |
66 | 1 |
Rash, Condition aggravated, Dermatitis atopic, Injection site pain, Skin lesion, |
||||
DUPILUMAB, FLUOCINONIDE, FLUOCINONIDE TOPICAL SOLUTION USP, 0.05%, NEMOLIZUMAB-ILTO, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, ROFLUMILAST, |
||||
| 3347 | 26591710 |
US |
39 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ERGOCALCIFEROL, CETIRIZINE HYDROCHLORIDE, |
||||
| 3348 | 26591851 |
US |
3 | 2 |
Dermatitis atopic, Rash, Pruritus, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3349 | 26591908 |
US |
1 | |
Dermatitis atopic, Skin fissures, Dry skin, Eczema, |
||||
DUPILUMAB, FLUTICASONE PROPIONATE, BUPROPION HYDROCHLORIDE, LORATADINE, LORATADINE ORAL, CETIRIZINE HCL, CETIRIZINE, FISH OIL, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, ABROCITINIB, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 3350 | 26591918 |
US |
2 | |
Dermatitis atopic, Intentional product misuse, |
||||
DUPILUMAB, |
||||
| 3351 | 26591919 |
US |
34 | 1 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 3352 | 26591966 |
US |
3 | 1 |
Dermatitis atopic, Rash erythematous, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 3353 | 26591984 |
US |
47 | 2 |
Constipation, Dermatitis atopic, Peripheral swelling, Pruritus, |
||||
DUPILUMAB, CETIRIZINE HYDROCHLORIDE, |
||||
| 3354 | 26591994 |
US |
55 | 1 |
Injection site pain, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3355 | 26591998 |
US |
32 | 2 |
Rash, Dermatitis atopic, Procedural pain, Tumour excision, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 3356 | 26592047 |
US |
26 | 2 |
Sleep disorder due to a general medical condition, Eczema, Pruritus, Injection site pain, Eye pruritus, Dermatitis atopic, Product preparation issue, |
||||
DUPILUMAB, ALBUTEROL SULFATE, FLUTICASONE PROPIONATE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 3357 | 26592055 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3358 | 26592056 |
US |
1 | |
Ocular hyperaemia, Eye pruritus, Dry eye, Eyelid skin dryness, Dry skin, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, DESONIDE, RUXOLITINIB, CETIRIZINE HYDROCHLORIDE, |
||||
| 3359 | 26592086 |
US |
2 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3360 | 26592105 |
US |
11 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, LEVOCETIRIZINE DIHYDROCHLORIDE, |
||||
| 3361 | 26592110 |
US |
57 | 2 |
Erythema, Pruritus, Skin burning sensation, Rash papular, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3362 | 26592112 |
US |
7 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3363 | 26592133 |
US |
25 | 2 |
Dermatitis atopic, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, |
||||
| 3364 | 26592135 |
US |
2 | |
Dermatitis atopic, Eczema, |
||||
DUPILUMAB, ALBUTEROL SULFATE, AMLODIPINE BESYLATE, BIOTIN, ESCITALOPRAM OXALATE, ESCITALOPRAM, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, LOSARTAN POTASSIUM, LOSARTAN, MAGNESIUM, NEMOLIZUMAB-ILTO, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, OMEPRAZOLE MAGNESIUM, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 3365 | 26592140 |
US |
2 | |
Lacrimation increased, Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, SERTRALINE HYDROCHLORIDE, |
||||
| 3366 | 26592149 |
US |
2 | |
Dermatitis atopic, Injection site pain, |
||||
DUPILUMAB, DEXAMETHASONE SODIUM PHOSPHATE, DOXYCYCLINE HYCLATE, DOXYCYCLINE, DOXYCLYCLINE HYCLATE, FENTANYL CITRATE, HYDROXYZINE PAMOATE, IOPAMIDOL, MONTELUKAST SODIUM, MONTELUKAST, MIRABEGRON, |
||||
| 3367 | 26592151 |
US |
1 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3368 | 26592174 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED, |
||||
| 3369 | 26592177 |
US |
8 | 1 |
Dermatitis atopic, Rash, Discomfort, Product dose omission issue, |
||||
DUPILUMAB, CETIRIZINE HYDROCHLORIDE, |
||||
| 3370 | 26592187 |
US |
42 | 2 |
Staphylococcal infection, Dermatitis atopic, Rash, Discomfort, |
||||
DUPILUMAB, CELECOXIB, HYDROCODONE BITARTRATE AND ACETAMINOPHEN, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, LOSARTAN POTASSIUM, LOSARTAN, PREGABALIN, METRONIDAZOLE, METRONIDAZOLE TOPICAL, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, LIRAGLUTIDE, DIAZEPAM, |
||||
| 3371 | 26592192 |
US |
37 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3372 | 26592198 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3373 | 26592213 |
US |
57 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3374 | 26592222 |
US |
44 | 2 |
Dermatitis atopic, Rash, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 3375 | 26592257 |
US |
8 | 2 |
Dermatitis atopic, Pruritus, Dry skin, Skin exfoliation, Erythema, Skin fissures, Therapeutic response shortened, |
||||
DUPILUMAB, MOMETASONE FUROATE, MOMETASONE, |
||||
| 3376 | 26592286 |
US |
14 | 1 |
Upper respiratory tract infection, Vomiting, Influenza like illness, Dermatitis atopic, |
||||
DUPILUMAB, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, ALBUTEROL SULFATE, FLUTICASONE PROPIONATE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, MONTELUKAST SODIUM, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, CETIRIZINE HYDROCHLORIDE, |
||||
| 3377 | 26592303 |
US |
65 | 2 |
Injection site bruising, Dermatitis atopic, Eczema, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 3378 | 26592311 |
US |
68 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, ROSUVASTATIN CALCIUM, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 3379 | 26592360 |
US |
43 | 2 |
Eczema, Product dose omission issue, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3380 | 26592457 |
US |
69 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3381 | 26592459 |
US |
9 | 2 |
Pruritus, Dry skin, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3382 | 26592464 |
US |
54 | 2 |
Herpes simplex, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3383 | 26592478 |
US |
28 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3384 | 26592512 |
US |
1 | |
Dermatitis atopic, Pruritus, Intentional product misuse, |
||||
DUPILUMAB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, IPRATROPIUM BROMIDE, BETAMETHASONE DIPROPIONATE, BRIMONIDINE TARTRATE, DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE, FAMOTIDINE, LATANOPROST, LISINOPRIL, MONTELUKAST SODIUM, MONTELUKAST, ROSUVASTATIN CALCIUM, TAMSULOSIN HYDROCHLORIDE, TIMOLOL MALEATE, TIMOLOL MALEATE OPHTHALMIC, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, ERGOCALCIFEROL, FLUTICASONE PROPIONATE AND SALMETEROL, |
||||
| 3385 | 26592662 |
US |
6 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, DOXEPIN HYDROCHLORIDE, DOXEPN HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE, |
||||
| 3386 | 26592667 |
US |
34 | 2 |
Dermatitis atopic, Psoriasis, Photosensitivity reaction, |
||||
DUPILUMAB, |
||||
| 3387 | 26592694 |
US |
1 | |
Injection site pain, Dermatitis atopic, Rash, Therapeutic response shortened, |
||||
DUPILUMAB, DUPILUMAB, ALBUTEROL SULFATE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, FLUTICASONE PROPIONATE AND SALMETEROL, |
||||
| 3388 | 26592741 |
US |
4 | 2 |
Fear of injection, Dry skin, Dermatitis atopic, Injection site pain, |
||||
DUPILUMAB, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 3389 | 26592799 |
US |
71 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3390 | 26592828 |
US |
2 | |
Dermatitis atopic, Blister, Crying, Skin exfoliation, Skin fissures, Pruritus, Product dose omission issue, |
||||
DUPILUMAB, AMLODIPINE BESYLATE, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM CAPSULE, DELAYED RELEASE, ESOMEPRAZOLE MAGNESIUM DIHYDRATE, ESOMEPRAZOLE MAGNESIUM DELAYED RELEASE CAPSULES, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, CRISABOROLE, FAMOTIDINE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, LORATADINE, LORATADINE ORAL, LOSARTAN POTASSIUM, LOSARTAN, METOPROLOL TARTRATE, METOROPROLOL TARTRATE, METOPROLOL, MONTELUKAST SODIUM, MONTELUKAST, RIMEGEPANT SULFATE, OXYCODONE HYDROCHLORIDE, CALCIUM, CARISOPRODOL, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, VITAMIN C, ERGOCALCIFEROL, VITAMIN E, LISDEXAMFETAMINE DIMESYLATE, |
||||
| 3391 | 26592847 |
US |
71 | 1 |
Injection site pain, Dermatitis atopic, |
||||
DUPILUMAB, ZOLPIDEM TARTRATE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE, HYDROCHLOROTHIAZIDE, ESOMEPRAZOLE MAGNESIUM, SPIRONOLACTONE, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, VALSARTAN, VALSARTAN ORAL, ERGOCALCIFEROL, |
||||
| 3392 | 26592892 |
US |
2 | |
Dermatitis atopic, Pain of skin, |
||||
DUPILUMAB, DUPILUMAB, MINOCYCLINE HYDROCHLORIDE, TOPIRAMATE, NORGESTIMATE AND ETHINYL ESTRADIOL, |
||||
| 3393 | 26592975 |
US |
2 | |
Dermatitis atopic, Therapeutic response decreased, Rash, |
||||
DUPILUMAB, LORATADINE, LORATADINE TABLET, ROSUVASTATIN, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, RIVAROXABAN, |
||||
| 3394 | 26592983 |
US |
1 | |
Dermatitis atopic, Pruritus, Acne, Eyelid skin dryness, Dry skin, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 3395 | 26593010 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 3396 | 26593057 |
US |
2 | |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, AMLODIPINE BESYLATE, BIOTIN, DOCUSATE SODIUM, DOCUSATE SODIUM 100MG, KETOCONAZOLE, KETOCONAZOLE FOAM, KETOCONAZOLE CREAM, 2%, LANSOPRAZOLE, LATANOPROST, PREDNISONE, |
||||
| 3397 | 26593180 |
US |
2 | |
Pruritus, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DIPHENHYDRAMINE HYDROCHLORIDE, PIMECROLIMUS, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, CETIRIZINE HYDROCHLORIDE, |
||||
| 3398 | 26593196 |
US |
4 | 1 |
Sleep disorder, Dermatitis atopic, Rash, Discomfort, |
||||
DUPILUMAB, |
||||
| 3399 | 26593198 |
US |
37 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, AMLODIPINE BESYLATE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 3400 | 26594329 |
US |
||
Rash, Dermatitis atopic, Therapeutic product effect incomplete, |
||||
NEMOLIZUMAB-ILTO, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30